Medical device and method for preventing adhesions

Patent metadata

Field	Value
Publication number	US-12150674-B2
Application number	US-202318351375-A
Country	US
Kind code	B2
Filing date	Jul 12, 2023
Priority date	Jan 10, 2020
Publication date	Nov 26, 2024
Grant date	Nov 26, 2024

Abstract

Methods and devices for treatment of a uterine cavity to prevent adhesions following a surgical intervention.

First claim

What is claimed is:

1. A method of treating a uterine cavity following a medical procedure therein, the method comprising:
deploying a device within the uterine cavity in a delivery profile, the device having a contact surface carrying a first pharmacological agent;
expanding the device to cause the contact surface to move into an expanded profile where the contact surface engages a surface of the uterine cavity to tamponade a bleeding at the surface of the uterine cavity and such that the first pharmacological agent releases from the contact surface into the surface of the uterine cavity over a first time interval;
collapsing the device to a collapsed profile to provide a barrier between uterine cavity surfaces wherein a second pharmacological agent releases from the contact surface over a second time interval, wherein the device is partially flattened while within the uterine cavity in the collapsed profile; and
removing the device in a removal profile after the second time interval.

2. The method of claim 1 , where the second time interval begins after the first time interval ends.

3. The method of claim 1 , wherein the first pharmacological agent is selected from a group constating of a hemostatic agent, an analgesic agent, an anti-cramping agent, and a non-steroidal anti-inflammatory agent, wherein the second pharmacological agent is selected from a group consisting of an anti-adhesion agent, an analgesic agent, an anti-cramping agent, and a non-steroidal anti-inflammatory agent.

4. The method of claim 1 , wherein the uterine cavity comprises an area of damaged tissue produced by a therapeutic procedure, wherein the area of damaged tissue is produced by a procedure selected from a group consisting of resection, curettage and ablation.

5. The method of claim 1 , wherein deploying the device includes trans-cervically introducing an elongate introducer into the uterine cavity and deploying the device from a passageway in the elongate introducer.

6. The method of claim 5 , wherein deploying the device includes allowing a spring element in the device to expand the device to a triangular shape in the uterine cavity.

7. The method of claim 6 , wherein the device comprises a thin film member disposed around the spring element, the thin film member has a fluid tight interior chamber to allow inflation of the thin film member.

8. The method of claim 7 , wherein deploying the device includes removing the elongate introducer from a uterus and a cervix and leaving a tether extending through a cervical canal, where the tether is connected to the device.

9. The method of claim 8 , wherein the tether is configured such that pulling on the tether, when the device is positioned in the uterine cavity, collapses the spring element and the thin film member to withdraw the device from the uterine cavity.

10. The method of claim 1 , wherein expanding the device includes inflating the device with a fluid injected through a lumen of a tether coupled to an interior chamber of the device.

11. The method of claim 10 , further comprising a pusher coupled to the tether, the pusher configured to be held stationary during deployment of the device.

12. The method of claim 10 , where the tether is detachable from the device.

13. The method of claim 10 , further comprising maintaining the device in the expanded profile for the first time interval by sealing the lumen of the tether.

14. The method of claim 13 , wherein sealing the lumen of the tether comprises actuating a stop mechanism in a portion of the tether outside the uterine cavity.

15. The method of claim 14 , wherein releasing the device comprises actuating the stop mechanism to unseal the lumen.

16. The method of claim 13 , further comprising a valve at a proximal end of the tether, wherein the valve is configured to seal a lumen of the tether.

17. The method of claim 16 , wherein the device is configured to be deflated to the collapsed profile through the valve.

18. The method of claim 1 , further comprising injecting at least one additional pharmacological agent through a tether channel into the uterine cavity.

19. The method of claim 1 , further comprising removing the device from the uterine cavity after the second time interval.

20. The method of claim 19 , wherein removing the device comprises pulling a tether coupled to the device outwardly from a cervical canal and uterine cavity.

Assignees

• Meditrina Inc

Inventors

• Truckai Csaba
• Shadduck John H

Classifications

• A61B2017/00995

  having a thin film · CPC title

• A61B2017/12004

  for haemostasis, for prevention of bleeding · CPC title

• A61B2090/0816

  for preventing adhesion · CPC title

• A61B2017/00893

  pharmaceutically effective · CPC title

• A61B2017/4216

  Operations on uterus, e.g. endometrium · CPC title